We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NV9 market cap is 0. The company's latest EPS is AUD -0.1002 and P/E is -0.80.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 0 | 15.18M | 0 | 0 |
| Operating Income | -10.65M | -12.19M | -5.95M | -25.38M | -20.76M |
| Net Income | -10.27M | -12.47M | -8.42M | -25.01M | -20.47M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 21.18M | 23.06M | 58.09M | 35.89M | 28.09M |
| Total Liabilities | 6.98M | 8.94M | 20.24M | 17.61M | 16.03M |
| Total Equity | 14.2M | 14.13M | 37.85M | 18.28M | 12.05M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -6.71M | -8.81M | -9.11M | -22.76M | -15.16M |
| Investing | 2.36M | N/A | N/A | -2.37M | N/A |
| Financing | 3.82M | 12.14M | 28.11M | 3.73M | 12.97M |
| Market Cap | 0 |
| Price to Earnings Ratio | -0.80 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.13 |
| Price to Book Ratio | 1.36 |
| Dividend Yield | - |
| Shares Outstanding | 204.34M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Kazia Therapeutics Limited |
| Address |
three international towers sydney, new south wales 2000 |
| Website | https://www.kaziatherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
